In breast cancer, a fully humanized, high-affinity monoclonal antibody (aNRP2-10) has recently been developed to specifically block the interaction between VEGF and its co-receptor neuropilin-2 (NRP2). This evidence concerns the gene NRP2 and breast cancer.